In vivo anti-tumour activity of recombinant MVM parvoviral vectors carrying the human interleukin-2 cDNA

Journal of Gene Medicine

Volumn 7, Issue 2, 2005, Pages 189-197

  El Bakkouri, Karim ^a   Servais, Charlotte ^d   Clément, Nathalie ^a,c   Cheong, Siew Chiat ^a   Franssen, Jean Denis ^b   Velu, Thierry ^a   Brandenburger, Annick ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Euroscreen SA   (Belgium)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Immunotherapy of cancer; Parvoviral vector

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 2; VIRUS VECTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYTOTOXICITY; EXPERIMENTAL DESIGN; GENETIC TRANSDUCTION; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; TUMOR CELL; TUMOR MODEL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WILD TYPE;

ANIMALS; CELL LINE; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; MICE; MINUTE VIRUS OF MICE; TRANSDUCTION, GENETIC;

MICE MINUTE VIRUS; PARVOVIRUS;

EID: 14844309278     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.653     Document Type: Article

References (55)

1. Fyfe G, Fisher R, Sznol M, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose proleukin interleukin-2 therapy. J Clin Oncol 1995; 13: 688.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105.
3. Den Otter W, Balemans L, Battermann JJ, et al. Local low-dose IL-2 therapy. Hepatogastroenterology 1999; 46(Suppl 1): 1280-1286.
4. Bubenik J, Den Otter W, Huland E. Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol Immunother 2000; 49: 116-122.
5. Atkins MB. Interleukin-2: clinical applications. Semin Oncol 2002; 29(suppl 7): 12-17.
6. Zier K, Gansbacher B. The impact of gene therapy on T cell function in cancer. Hum Gene Ther 1995; 6: 1259-1264.
7. Parmiani G, Rodolfo M, Melani C. Immunological gene therapy with ex vivo gene-modified tumour cells: a critique and a reappraisal. Hum Gene Ther 2000; 11: 1269-1275.
8. Haag A, Menten P, Van Damme J, et al. Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors: generation of antitumor responses in recipient mice. Hum Gene Ther 2000; 11: 597-609.
9. Peter I, Nawrath M, Kamarashev J, et al. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther 2002; 9: 597-605.
10. Levraud JP, Duffour MT, Cordier L, et al. IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL. J Immunol 1997; 158: 3335-3343.
11. + T-cell immunity and NK activity. Cancer Gene Ther 2001; 8: 321-332.
12. Russell SJ. Lymphokine gene therapy for cancer. Immunol Today 1990; 11: 196-200.
13. Rommelaere J, Cornelis JJ. Antineoplastic activity of parvoviruses. J Virol Methods 1991; 33: 233-251.
14. Brandenburger A, Legendre D, Avalosse B, et al. NS-1 and NS-2 proteins may act synergistically in the cytopathogenicity of parvovirus MVMp. Virology 1990; 174: 576-584.
15. Caillet-Fauquet P, Perros M, Brandenburger A, et al. Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. EMBO J 1990; 9: 2989-2995.
16. Cornelis JJ, Salomé N, Dinsart C, et al. Vectors based on autonomous parvoviruses: novel tools to treat cancer? J Gene Med 2004; 6: S193-S202.
17. Russell SJ, Brandenburger A, Flemming CL, et al. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992; 66: 2821-2828.
18. Brown CS, DiSumma FM, Rommelaere J, et al. Production of recombinant H1 parvovirus stocks devoid of replication-competent virus. Hum Gene Ther 2002; 13: 2135-2145.
19. Wetzel K, Menten P, Opdënakker G, et al. Transduction of human MCP-3 by a parvoviral vector induces leukocyte infiltration and reduces growth of human cervical carcinoma cell xenografts. J Gene Med 2001; 3: 326-337.
20. Giesse N, Raykov Z, DeMartino L, et al. Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther 2002; 9: 432-442.
21. Brandenburger A, Coessens E, El Bakkouri K, et al. Influence of sequence and size of DNA on packaging efficiency of parvovirus MVM-based vectors. Hum Gene Ther 1999; 10: 1229-1238.
22. El Bakkouri K, Clément N, Velu T, et al. Amplification of MVM(p) vectors through serial infection of a new packaging cell line. Tumor Targeting 1999; 4: 210-217.
23. Cheong SC, Clément N, Velu T, et al. A novel method for the titration of recombinant virus stocks by ELISPOT assay, J Virol Methods 2003; 109: 119-124.
24. Shein HM, Enders JF. Multiplication and cytopathogenicity of simian vacuolating virus 40 in cultures of human tissues. Proc Soc Exp Biol Med 1962; 109: 495-500.
25. Rao CN, Brinker JM, Kefalides NA. Changes in the subunit composition of laminin during the increased tumorigenesis of mouse A9 cells. Connect Tissue Res 1991; 25: 321-329.
26. Brattain MG, Strobel-Stevens J, Fine D, et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142-2146.
27. Szpirer C, Szpirer J. A mouse hepatoma cell line which secretes several serum proteins including albumin and alpha-foetoprotein. Differenciation 1975; 4: 85-91.
28. Bertram JS, Janik P. Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture. Cancer Lett 1980; 11: 63-73.
29. Fidler JJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975; 35: 218-224.
30. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979; 63: 541-548.
31. Klebe RJ, Chen T, Ruddle FH. Controlled production of proliferating somatic cell hybrids. J Cell Biol 1970; 45: 74-82.
32. Patel PM, Flemming CL, Russell SJ, et al. Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. Br J Cancer 1993; 68: 295-302.
33. Dunn TB, Potter M. A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst 1957; 18: 587.
34. North RJ. The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1 + 2-T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression. Cancer Immunol Immunother 1984; 18: 75-79.
35. Brandenburger A, Russell S. A novel packaging system for the generation of helper-free oncolytic MVM vector stocks. Gene Ther 1996; 3: 927-931.
36. Gearing AJ, Thorpe R. The international standard for human interleukin-2. Calibration by international collaborative study. J Immunol Methods 1988; 114: 3-9.
37. Van Pachterbeke C, Tuynder M, Cosyn JP, et al. Parvovirus H-1 inhibits growth of short-term tumor-derived but not normal mammary tissue cultures. Int J Cancer 1993; 55: 672-677.
38. Van Pachterbeke C, Tuynder M, Brandenburger A, et al. Varying sensitivity of human mammary carcinoma cells to the toxic effect of parvovirus H-1. Eur J Cancer 1997; 33: 1648-1653.
39. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
40. Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
41. Haddada H, Ragot T, Cordier L, et al. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4: 703-711.
42. Bonnekoh B, Greenhalgh DA, Chen SH, et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model. J Invest Dermatol 1998; 110: 867-871.
43. Schneeberger A, Koszik F, Schmidt W, et al. The tumorigenicity of IL2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role. J Immunol 1999; 162: 6650-6657.
44. Barnard AL, Farzaneh F, Gaken J, et al. Local versus systemic interleukin-2: tumor formation by wild-type and B7-1-positive murine melanoma cells. Cancer Gene Ther 2000; 7: 207-214.
45. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13: 169-183.
46. Fakhrai H, Shawler DL, Gjerset R, et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 1995; 6: 591-601.
47. Schmidt W, Schweighoffer T, Herbst E, et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci U S A 1995; 92: 4711-4714.
48. Melcher A, Todryk S, Hardwick N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4: 581-587.
49. Op De Beeck A, Caillet-Fauquet P. The NS1 protein of the autonomous parvovirus minute virus of mice blocks cellular DNA replication: a consequence of lesions to the chromatin? J Virol 1997; 71: 5323-5329.
50. Ohshima T, Iwama M, Ueno Y, et al. Induction of apoptosis in vitro and in vivo by H-1 parvovirus infection, J Gen Virol 1998; 79: 3067-3071.
51. Rayet B, Lopez-Guerrero JA, Rommelaere J, et al. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha signalling pathway. J Virol 1998; 72: 8893-8903.
52. Moehler M, Blechacz B, Weiskopf N, et al. Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. Cancer Gene Ther 2001; 8: 158-167.
53. Ran Z, Rayet B, Rommelaere J, et al. Parvovirus H-1-induced cell death: influence of intracellular NAD consumption on the regulation of necrosis and apoptosis. Virus Res 1999; 65: 161-174.
54. Moehler M, Zeidler M, Schede J, et al. Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Caner Gene Ther 2003; 10: 477-480.
55. Brandenburger A, Velu T. Autonomous parvovirus vectors: preventing the generation of wild-type or replication-competent virus. J Gene Med 2004; 6: S203-S211.